Chrono snares $32M in Series A for wearable smoking cessation device

SmartStop smoking cessation system--Courtesy of Chrono Therapeutics

Chrono Therapeutics secured $32 million in Series A funding the company will use to complete the development and clinical studies of its wearable SmartStop smoking cessation system.

The financing round was led by Canaan Partners and 5AM Ventures with additional participation from Fountain Healthcare Partners, the Mayo Clinic and GE Ventures. Wende Hutton, general partner with Canaan Partners, Jim Young of 5AM Ventures and Aidan King of Fountain will join the board of directors, the Hayward, CA-based company said in a release.

The SmartStop smoking cessation system monitors peak craving times for smokers throughout the day and delivers nicotine to suppress the cravings. Additionally, Chrono Therapeutics offers real-time behavioral support for smokers to kick the habit. SmartStop uses Bluetooth technology that links smokers with a digital support program that gives guidance to help deal with cravings.

Smoking kills more than 400,000 people in the U.S. every year, and is blamed for about one in 5 deaths in the country, the company said in a release, citing statistics from the Centers for Disease Control. Seventy percent of the 45 million smokers in America have said they want to quit, with the average smoker attempting to kick the habit between 8 and 10 times.

"Smoking costs people their health and eventually their lives, but current technologies like nicotine gums and patches are not effective in enabling smokers to quit permanently because they do not address the cyclical nature of nicotine cravings and offer behavioral support," Alan Levy, chief executive of Chrono, said in a release. "We believe we have a very compelling technology that will solve many of the problems that make smoking cessation so difficult."

Under the Affordable Care Act, smoking-cessation treatments are now reimbursable, making nicotine addiction treatment a potentially lucrative market for new technologies.

- read the release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.